Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
465 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Melanoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2014', provides an overview of the Metastatic Melanoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Metastatic Melanoma Overview 7 Therapeutics Development 8 Metastatic Melanoma - Therapeutics under Development by Companies 10 Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Melanoma - Pipeline Products Glance 19 Metastatic Melanoma - Products under Development by Companies 22 Metastatic Melanoma - Products under Investigation by Universities/Institutes 29 Metastatic Melanoma - Companies Involved in Therapeutics Development 30 Metastatic Melanoma - Therapeutics Assessment 95 Drug Profiles 114 Metastatic Melanoma - Recent Pipeline Updates 333 Metastatic Melanoma - Dormant Projects 437 Metastatic Melanoma - Discontinued Products 440 Metastatic Melanoma - Product Development Milestones 441 Appendix 450
List of Tables Number of Products under Development for Metastatic Melanoma, H2 2014 22 Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2014 23 Number of Products under Development by Companies, H2 2014 25 Number of Products under Development by Companies, H2 2014 (Contd..1) 26 Number of Products under Development by Companies, H2 2014 (Contd..2) 27 Number of Products under Development by Companies, H2 2014 (Contd..3) 28 Number of Products under Development by Companies, H2 2014 (Contd..4) 29 Number of Products under Development by Companies, H2 2014 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H2 2014 32 Comparative Analysis by Late Stage Development, H2 2014 33 Comparative Analysis by Clinical Stage Development, H2 2014 34 Comparative Analysis by Early Stage Development, H2 2014 35 Products under Development by Companies, H2 2014 36 Products under Development by Companies, H2 2014 (Contd..1) 37 Products under Development by Companies, H2 2014 (Contd..2) 38 Products under Development by Companies, H2 2014 (Contd..3) 39 Products under Development by Companies, H2 2014 (Contd..4) 40 Products under Development by Companies, H2 2014 (Contd..5) 41 Products under Development by Companies, H2 2014 (Contd..6) 42 Products under Investigation by Universities/Institutes, H2 2014 43 Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 44 Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 45 Metastatic Melanoma - Pipeline by Vical Incorporated, H2 2014 46 Metastatic Melanoma - Pipeline by Amgen Inc., H2 2014 47 Metastatic Melanoma - Pipeline by Sanofi, H2 2014 48 Metastatic Melanoma - Pipeline by AstraZeneca PLC, H2 2014 49 Metastatic Melanoma - Pipeline by GlaxoSmithKline plc, H2 2014 50 Metastatic Melanoma - Pipeline by Genentech, Inc., H2 2014 51 Metastatic Melanoma - Pipeline by Agenus, Inc., H2 2014 52 Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2014 53 Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2014 54 Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2014 55 Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2014 56 Metastatic Melanoma - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 57 Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 58 Metastatic Melanoma - Pipeline by Novartis AG, H2 2014 59 Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2014 60 Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 61 Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2014 62 Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 63 Metastatic Melanoma - Pipeline by Celgene Corporation, H2 2014 64 Metastatic Melanoma - Pipeline by Bayer AG, H2 2014 65 Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2014 66 Metastatic Melanoma - Pipeline by Merck KGaA, H2 2014 67 Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2014 68 Metastatic Melanoma - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 69 Metastatic Melanoma - Pipeline by AVAX Technologies, Inc., H2 2014 70 Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2014 71 Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2014 72 Metastatic Melanoma - Pipeline by NeoStem, Inc., H2 2014 73 Metastatic Melanoma - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 74 Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2014 75 Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2014 76 Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 77 Metastatic Melanoma - Pipeline by Galapagos NV, H2 2014 78 Metastatic Melanoma - Pipeline by PCI Biotech AS, H2 2014 79 Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2014 80 Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2014 81 Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2014 82 Metastatic Melanoma - Pipeline by Colby Pharmaceutical Company, H2 2014 83 Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2014 84 Metastatic Melanoma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 85 Metastatic Melanoma - Pipeline by Affichem, H2 2014 86 Metastatic Melanoma - Pipeline by Polyphor Ltd., H2 2014 87 Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2014 88 Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2014 89 Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2014 90 Metastatic Melanoma - Pipeline by SBI Biotech Co., Ltd., H2 2014 91 Metastatic Melanoma - Pipeline by AB Science, H2 2014 92 Metastatic Melanoma - Pipeline by CureTech Ltd., H2 2014 93 Metastatic Melanoma - Pipeline by WntResearch AB, H2 2014 94 Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2014 95 Metastatic Melanoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 96 Metastatic Melanoma - Pipeline by n.v. BRUCELLS s.a., H2 2014 97 Metastatic Melanoma - Pipeline by Cavion LLC, H2 2014 98 Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2014 99 Metastatic Melanoma - Pipeline by Immunophotonics Inc, H2 2014 100 Metastatic Melanoma - Pipeline by Kite Pharma, Inc., H2 2014 101 Metastatic Melanoma - Pipeline by Sanofi Pasteur SA, H2 2014 102 Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H2 2014 103 Metastatic Melanoma - Pipeline by Vaxeal Holding SA, H2 2014 104 Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H2 2014 105 Metastatic Melanoma - Pipeline by AbbVie Inc., H2 2014 106 Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2014 107 Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2014 108 Assessment by Monotherapy Products, H2 2014 109 Assessment by Combination Products, H2 2014 110 Number of Products by Stage and Target, H2 2014 113 Number of Products by Stage and Mechanism of Action, H2 2014 119 Number of Products by Stage and Route of Administration, H2 2014 124 Number of Products by Stage and Molecule Type, H2 2014 127 Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H2 2014 347 Metastatic Melanoma - Dormant Projects, H2 2014 451 Metastatic Melanoma - Discontinued Products, H2 2014 454
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
